Eiger BioPharmaceuticals (EIGR) Given a $34.00 Price Target at Oppenheimer

Eiger BioPharmaceuticals (NASDAQ:EIGR) has been assigned a $34.00 price objective by stock analysts at Oppenheimer in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s target price indicates a potential upside of 167.72% from the company’s previous close.

Several other analysts have also recently commented on EIGR. Wedbush reiterated an “ourperform” rating and issued a $34.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Monday, August 14th. Piper Jaffray Companies reiterated a “buy” rating and issued a $36.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Tuesday, August 15th. Zacks Investment Research cut shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. ValuEngine upgraded shares of Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Roth Capital initiated coverage on shares of Eiger BioPharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $35.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Eiger BioPharmaceuticals currently has a consensus rating of “Buy” and an average price target of $30.43.

Shares of Eiger BioPharmaceuticals (EIGR) opened at $12.70 on Thursday. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19. Eiger BioPharmaceuticals has a 52 week low of $6.10 and a 52 week high of $13.95.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.28) by $0.18. equities analysts forecast that Eiger BioPharmaceuticals will post -5.08 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Wedbush Securities Inc. acquired a new position in Eiger BioPharmaceuticals during the third quarter worth about $114,000. Susquehanna International Group LLP acquired a new position in Eiger BioPharmaceuticals during the second quarter worth about $114,000. Bank of New York Mellon Corp raised its position in Eiger BioPharmaceuticals by 6.4% during the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 871 shares during the last quarter. LMR Partners LLP acquired a new position in Eiger BioPharmaceuticals during the second quarter worth about $116,000. Finally, JPMorgan Chase & Co. raised its position in Eiger BioPharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 8,748 shares during the last quarter. Institutional investors own 47.06% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Eiger BioPharmaceuticals (EIGR) Given a $34.00 Price Target at Oppenheimer” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/08/eiger-biopharmaceuticals-eigr-given-a-34-00-price-target-at-oppenheimer.html.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Analyst Recommendations for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply